SuanFarma-Header SuanFarma-Header

X

Find Ophthalmology Drugs in Phase IV Development in ISRAEL

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Sodium Hyaluronate

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 07, 2020

            Details:

            The clinical trial is designed to demonstrate the clinical efficacy and safety of LO2A in DES patients with Sjögren's syndrome. Phase IV study aims at expanding LO2A's current approved status.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Sodium Hyaluronate

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bonus BioGroup

            Deal Size: $7.4 million Upfront Cash: Undisclosed

            Deal Type: Agreement January 16, 2020

            Details:

            This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.